The purpose of this study is to find out whether certain genetic differences may explain why some severely burned patients continue to have high lactic acid levels in their blood even after receiving proper medical treatment. We will collect a small blood sample from each patient and analyze their DNA to look for gene variations related to how the body produces energy. Understanding this may help doctors better predict which patients are at higher risk and develop more personalized treatments in the future.THIS STUDY IS ENROLLING BY INVITATION ONLY - Burn patients with TBSA equal to or greater than 20% will be identified by burn unit team on the burn service, this is comprised of attending, APPs, and fellow. Patients with TBSA of 20% or greater will have the resuscitation protocol activated, and resuscitation will be followed with serial lactate. Response to resuscitation will be assessed with multiple parameters, including lactate, urine output, and overall clinical status. Once these patients are identified, they will be approached by the team, and the research study will be discussed with them. If they are intubated or not in a state to provide consent due to critical clinical condition, the study will be discussed with LAR who will sign on patient's behalf. This will be done in person.

This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.THIS STUDY IS ENROLLING BY INVITATION ONLY

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

The purpose of this study is to compare the two approaches for monitoring pancreatic cysts. The study doctors want to compare more frequent monitoring vs less frequent monitoring in order to learn which monitoring method leads to better outcome for patients with pancreatic cysts.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at Indiana University Simon Comprehensive Cancer Center (IUSCCC), please contact theIU Clinical Trials Office at Email: iutrials@iu.edu Phone: (317) 278-5632